The Skinny Label Crisis in Pharma Licensing: Innovation vs. Affordability

The Skinny Label Crisis in Pharma Licensing: Innovation vs. Affordability The “skinny label” strategy has emerged as a contentious battleground in pharmaceutical patent law, allowing generic manufacturers to launch products early by carving out patented uses from their FDA-approved labels under Section VIII of the Hatch-Waxman Act. This regulatory carve-out enables market entry for unpatented […]